DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161525

Study of variation in prices of oral antiplatelet drugs available in Indian market

Abhilasha Rashmi, Sharmada Nerlekar, Kumar Rajeev

Abstract


Background: Coronary artery disease is one of the most prevalent causes of death and disability in developed and developing countries. There is a wide variation in the prices of oral antiplatelet drugs marketed in India. Thus, a study was planned to find out the variation in cost in the oral antiplatelet drugs available in India either as a single drug or in combination and to evaluate the difference in cost of various brands of the same antiplatelet drug by calculating percentage variation in cost.

Methods: Cost of oral antiplatelet drugs manufactured by different pharmaceutical companies, in the same strength and dosage forms was obtained from “current index of medical specialties” October 2015-January 2016. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in cost per 10 tablets was calculated.

Results: Percentage variation in cost for oral antiplatelet drugs marketed in India was found to be-clopidogrel 75 mg (1067.3%), clopidogrel 150 mg tablet (148.7%), prasugrel 5 mg (94.4%), aspirin 150 mg (69.8%), prasugrel 10 mg (54.8%), aspirin 75 mg (51.5%), clopidogrel 300 mg tablet (42.9%) and ticlopidine 250 mg (32%). The lowest percent cost variation found is ticagrelor 90 mg (0%). In combination therapy the highest price variation (235.6%) was found for aspirin (75 mg)+clopidogrel (75 mg) followed by aspirin (150 mg)+clopidogrel (75 mg) (24.2%).

Conclusions: There is a wide difference in the cost of different brands of oral antiplatelet drugs available in India. The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy.


Keywords


Antiplatelet drugs, Price variation, Cost ratio

Full Text:

PDF

References


Hackner SG. Antiplatelet drugs; what, when, and how. Cornell University Veterinary Specialists. Available at, www.cuvs.org.

Akila L, Rani RJ. Cost analysis of different brands of antianginal drugs available in India. Int J Basic Clin Pharmacol. 2015;4:860-3.

Wong CK. The Role of antiplatelet agents. BPJ. 2009;19:32-37.

Panchal SS, Pandit PR, Phatak AM, Lohi KM. Cost analysis of antiretroviral agents available in India. Int J Basic Clin Pharmacol. 2015;4:479-82.

Current index of medical specialties. 37th year, 2015-2016;131-5.

Mir SA. Cost analysis of different brands of antimicrobial agents available in India. Int J Basic Clin Pharmacol. 2016;5:85-9.

Ticagrelor drug information. Drugs Update India. Available at www.drugsupdate.com.

Axcer 90 mg tablet. Available at www.medplusmart.com.

National pharmaceutical pricing authority; price notification. August 2014. Available at www.nppaindia.nic.in.

Mir SA. A calm look at the cost of various brands of antiasthmatic drugs available in India. Int J Basic Clin Pharmacol. 2016;5:142-5.

Chawan VS, Gawand KV, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Clin Pharmacol. 2014;3:954-7.

Piette JD, Beard A, Rosland AM, McHorney CA. Beliefs that influence cost -related medication non-adherence among the “haves” and “have nots” with chronic diseases. Patient Prefer Adherence. 2011;5:389-96.

Kardas P, Bishai WR. Compliance in infective medicine. Adv Stud Med. 2006;6(7):652-8.

Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21.

Jean-Michel G, Pamela GC, Paula AG, Lawrence WW, Karen MK, Hunink MG, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346(23):1800-6.

Mike C, John H, John G. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK-aspirin, dipyridamole and aspirin-dipyridamole. PharmacoEconomics. November 1999;16(5pt2):577-93.